Germany's Medios 2025 revenue beats estimates on international business expansion

Medios AG

26/03/2026 06:50

Overview

Germany specialty pharma provider's 2025 revenue grew 10%, beating analyst expectations

Company improved profitability with higher EBITDA margin and earnings per share

Pharmaceutical Supply and International Business segments were main contributors to growth

Outlook

Medios expects 2026 revenue between €2.0 bln and €2.12 bln

Company forecasts 2026 EBITDA pre of €94 mln to €102 mln

Medios anticipates EBITDA pre margin rising to around 4.8% in 2026

Result Drivers

SEGMENT PERFORMANCE - Pharmaceutical Supply and International Business segments were main contributors to revenue and profitability growth

INTERNATIONAL BUSINESS EXPANSION - International Business segment posted strong revenue and EBITDA pre growth after joining the group in June 2024

ORGANIC GROWTH - Organic revenue and EBITDA pre growth contributed to overall performance

Company press release: ID:nEQ1KdFV9a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
EUR 2.08 bln
EUR 2.01 bln (5 Analysts)
FY Adjusted Free Cash Flow
EUR 52.30 mln
FY EBITDA
EUR 93.10 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Medios AG is €25.00, about 83.8% above its March 25 closing price of €13.60

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)